OpenURL Connection Search

Select item for more details and to access through your institution.

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Published in:
Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00273-0
By:
- Kaneko, Yutaro;
- Hatano, Ryo;
- Hirota, Naoto;
- Isambert, Nicolas;
- Trillet-Lenoir, Véronique;
- You, Benoit;
- Alexandre, Jérôme;
- Zalcman, Gérard;
- Valleix, Fanny;
- Podoll, Thomas;
- Umezawa, Yoshimi;
- Takao, Seiichi;
- Iwata, Satoshi;
- Hosono, Osamu;
- Taguchi, Tetsuo;
- Yamada, Taketo;
- Dang, Nam H.;
- Ohnuma, Kei;
- Angevin, Eric;
- Morimoto, Chikao
Publication type:
Article
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Published in:
British Journal of Cancer, 2017, v. 116, n. 9, p. 1126, doi. 10.1038/bjc.2017.62
By:
- Angevin, Eric;
- Isambert, Nicolas;
- Trillet-Lenoir, Véronique;
- You, Benoit;
- Alexandre, Jérôme;
- Zalcman, Gérard;
- Vielh, Philippe;
- Farace, Françoise;
- Valleix, Fanny;
- Podoll, Thomas;
- Kuramochi, Yu;
- Miyashita, Itaru;
- Hosono, Osamu;
- Dang, Nam H;
- Ohnuma, Kei;
- Yamada, Taketo;
- Kaneko, Yutaro;
- Morimoto, Chikao
Publication type:
Article
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Published in:
2017
By:
- Angevin, Eric;
- Isambert, Nicolas;
- Trillet-Lenoir, Véronique;
- You, Benoit;
- Alexandre, Jérôme;
- Zalcman, Gérard;
- Vielh, Philippe;
- Farace, Françoise;
- Valleix, Fanny;
- Podoll, Thomas;
- Kuramochi, Yu;
- Miyashita, Itaru;
- Hosono, Osamu;
- Dang, Nam H;
- Ohnuma, Kei;
- Yamada, Taketo;
- Kaneko, Yutaro;
- Morimoto, Chikao
Publication type:
journal article

Found: 3

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.